| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7390461 | Value in Health Regional Issues | 2015 | 5 Pages |
Abstract
Metformin appears to provide better value for money than does acarbose. Findings from this study are consistent with those from previous studies that metformin is undoubtedly the first choice in the management of T2DM, with significant glucose-lowering effects and low treatment costs.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Shuyan PhD, Zhiliu PhD, Lizheng PhD, Monika PhD, Huimei MPA, Hengjin PhD,